
BenevolentAI SA
AEX:BAI

Net Margin
BenevolentAI SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
UK |
![]() |
BenevolentAI SA
AEX:BAI
|
11.6m EUR |
-1 056%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
765.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
399.9B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
207.3B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
180.7B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.3B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.5B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
138.2B USD |
13%
|
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on BenevolentAI SA's most recent financial statements, the company has Net Margin of -1 056%.